Last reviewed · How we verify

Rocuronium Injectable Solution

Federal University of São Paulo · FDA-approved active Small molecule

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis.

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis. Used for Facilitation of endotracheal intubation during anesthesia induction, Maintenance of neuromuscular blockade during general anesthesia and mechanical ventilation.

At a glance

Generic nameRocuronium Injectable Solution
Also known asrocuronium
SponsorFederal University of São Paulo
Drug classNon-depolarizing neuromuscular blocking agent
TargetNicotinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Rocuronium binds to nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and triggering muscle contraction. This results in flaccid paralysis of skeletal muscles. The drug is used during anesthesia to facilitate intubation and maintain muscle relaxation during surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: